Rigel Pharmaceuticals Company Profile (NASDAQ:RIGL)

About Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company's clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RIGL
  • CUSIP: 76655960
  • Web: www.rigel.com
Capitalization:
  • Market Cap: $294.81 million
  • Outstanding Shares: 124,392,000
Average Prices:
  • 50 Day Moving Avg: $2.37
  • 200 Day Moving Avg: $2.65
  • 52 Week Range: $1.94 - $4.38
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.39
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $10.34 million
  • Price / Sales: 28.51
  • Book Value: $0.56 per share
  • Price / Book: 4.23
Profitability:
  • EBIDTA: ($67,710,000.00)
  • Net Margins: -354.14%
  • Return on Equity: -105.86%
  • Return on Assets: -82.23%
Debt:
  • Current Ratio: 5.28%
  • Quick Ratio: 5.28%
Misc:
  • Average Volume: 757,011 shs.
  • Beta: 1.24
  • Short Ratio: 5.13
 

Frequently Asked Questions for Rigel Pharmaceuticals (NASDAQ:RIGL)

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.01. Rigel Pharmaceuticals had a negative return on equity of 105.86% and a negative net margin of 354.14%. During the same quarter in the prior year, the firm posted ($0.15) EPS. View Rigel Pharmaceuticals' Earnings History.

When will Rigel Pharmaceuticals make its next earnings announcement?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Rigel Pharmaceuticals.

Where is Rigel Pharmaceuticals' stock going? Where will Rigel Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 1 year target prices for Rigel Pharmaceuticals' stock. Their predictions range from $5.00 to $11.00. On average, they expect Rigel Pharmaceuticals' share price to reach $6.75 in the next twelve months. View Analyst Ratings for Rigel Pharmaceuticals.

What are analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (9/20/2017)
  • 2. Jefferies Group LLC analysts commented, "RIGL is on track to submit an NDA for fosta in ITP in 1Q17; next major catalyst could be FDA acceptance by ~May given mixed Ph3 data & limited FDA interactions following Ph3 data. YE16 cash of ~$75M, plus net proceeds of $43M from recent offering, should be sufficient at least for next 12 months including pre-commercial activities, per RIGL. If fosta is approved in ITP, we see >50% upside to our current PT of $5." (3/8/2017)
  • 3. BMO Capital Markets analysts commented, "We remain focused on fostamatinib's pending NDA submission, which we believe supports approval given clear and consistent benefit in ITP, despite one pivotal trial missing statistical significance. We believe reaching an FDA Adcom would be a positive event, as a panel of clinicians would likely recommend approval. Additionally, we believe the fostamatinib addressable patient population is larger than the 18% stable response rate, as real world use would include patients who maintain platelet counts greater than 30K/ul, according to physician feedback. We rate RIGL shares Outperform." (3/8/2017)

Who are some of Rigel Pharmaceuticals' key competitors?

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:

  • Raul R Rodriguez, President, Chief Executive Officer, Director
  • Ryan D. Maynard, Chief Financial Officer and Executive Vice President
  • Dolly A. Vance, Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
  • Eldon C. Mayer III, Executive Vice President, Chief Commercial Officer
  • Anne-Marie Duliege M.D., Chief Marketing Officer
  • Keith A. Katkin, Director
  • Brian L. Kotzin M.D., Director
  • Bradford S. Goodwin, Independent Director
  • Gary A. Lyons, Independent Director
  • Walter H. Moos Ph.D., Independent Director

Who owns Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.76%), Vanguard Group Inc. (4.86%), Palo Alto Investors LLC (3.10%), NEA Management Company LLC (2.65%), State Street Corp (1.76%) and Marshall Wace North America L.P. (1.62%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege and Donald G Payan. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Who sold Rigel Pharmaceuticals stock? Who is selling Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Palo Alto Investors LLC, DAFNA Capital Management LLC, New York State Common Retirement Fund, California State Teachers Retirement System, Bank of New York Mellon Corp, Goldman Sachs Group Inc. and ProShare Advisors LLC. View Insider Buying and Selling for Rigel Pharmaceuticals.

Who bought Rigel Pharmaceuticals stock? Who is buying Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., B. Riley Financial Inc., Paulson & CO. Inc., Northern Trust Corp, Macquarie Group Ltd., Candriam Luxembourg S.C.A., State Street Corp and State of Wisconsin Investment Board. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy Rigel Pharmaceuticals stock?

Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $2.37.


MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  312
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Rigel Pharmaceuticals (NASDAQ:RIGL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.75 (184.81% upside)

Analysts' Ratings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017Jefferies Group LLCReiterated RatingBuy$5.00HighView Rating Details
6/19/2017BMO Capital MarketsReiterated RatingOutperform -> Outperform$4.00 -> $5.00LowView Rating Details
5/3/2017HC WainwrightReiterated RatingBuy$6.00MediumView Rating Details
11/2/2016Piper Jaffray CompaniesSet Price TargetBuy$11.00N/AView Rating Details
8/3/2016J P Morgan Chase & CoReiterated RatingBuy$5.00N/AView Rating Details
4/23/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Earnings History by Quarter for Rigel Pharmaceuticals (NASDAQ RIGL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.14)N/AView Earnings Details
8/1/2017Q2 2017($0.15)($0.16)$2.05 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.12)($0.13)$4.30 million$3.58 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.17)($0.16)$4.25 million$3.00 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.24)$3.97 million$3.76 millionViewListenView Earnings Details
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)$1.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rigel Pharmaceuticals (NASDAQ:RIGL)
2017 EPS Consensus Estimate: ($0.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rigel Pharmaceuticals (NASDAQ:RIGL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Ownership Percentage: 5.21%
Institutional Ownership Percentage: 88.17%
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Anne-Marie DuliegeInsiderSell5,000$2.69$13,450.00View SEC Filing  
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Rigel Pharmaceuticals (NASDAQ:RIGL)
Latest Headlines for Rigel Pharmaceuticals (NASDAQ:RIGL)
Source:
DateHeadline
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - September 21 at 12:02 AM
prnewswire.com logoRigel to Present at Cantor Fitzgerald Global Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - September 20 at 8:25 AM
finance.yahoo.com logoRigel to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 8:25 AM
americanbankingnews.com logoRigel Pharmaceuticals (RIGL) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - September 13 at 4:30 PM
americanbankingnews.com logoValuEngine Downgrades Rigel Pharmaceuticals, Inc. (RIGL) to Strong Sell
www.americanbankingnews.com - September 6 at 11:02 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 2 at 12:36 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : September 1, 2017
finance.yahoo.com - September 2 at 8:04 AM
streetinsider.com logoRigel Pharma (RIGL) Appoints Brian Kotzin, MD to Board - StreetInsider.com
www.streetinsider.com - August 26 at 8:53 AM
streetinsider.com logoRigel Pharma (RIGL) Appoints Brian Kotzin, MD to Board
www.streetinsider.com - August 25 at 10:56 AM
streetinsider.com logoRigel Pharma (RIGL) Appoints Brian Kotzin, MD to Board
www.streetinsider.com - August 25 at 10:56 AM
finance.yahoo.com logoRigel Welcomes Brian Kotzin, M.D. to Board of Directors
finance.yahoo.com - August 25 at 10:56 AM
finance.yahoo.com logoRigel Welcomes Brian Kotzin, M.D. to Board of Directors
finance.yahoo.com - August 25 at 10:56 AM
seekingalpha.com logoStrong Quarterly Numbers Make Rigel Look Undervalued
seekingalpha.com - August 12 at 7:25 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 8 at 2:44 PM
americanbankingnews.com logoZacks Investment Research Downgrades Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to Sell
www.americanbankingnews.com - August 5 at 7:14 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. Expected to Post FY2021 Earnings of $0.12 Per Share (NASDAQ:RIGL)
www.americanbankingnews.com - August 3 at 5:00 PM
seekingalpha.com logoRigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 2 at 3:55 PM
prnewswire.com logoRigel Announces Second Quarter 2017 Financial Results and Provides Company Update - PR Newswire (press release)
www.prnewswire.com - August 2 at 3:55 PM
rttnews.com logoEARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q2 Earnings Report
www.rttnews.com - August 2 at 7:14 AM
finance.yahoo.com logoRigel Announces Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - August 2 at 7:14 AM
finance.yahoo.com logoRigel reports 2Q loss
finance.yahoo.com - August 2 at 7:14 AM
finance.yahoo.com logoEdited Transcript of RIGL earnings conference call or presentation 1-Aug-17 9:00pm GMT
finance.yahoo.com - August 2 at 7:14 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 1 at 10:30 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - July 29 at 12:58 PM
finance.yahoo.com logoRigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results
finance.yahoo.com - July 26 at 6:49 AM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : July 24, 2017
finance.yahoo.com - July 25 at 5:24 AM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 25 at 5:24 AM
americanbankingnews.com logoFinancial Contrast: Rigel Pharmaceuticals (RIGL) and Ocata Therapeutics (OCAT)
www.americanbankingnews.com - July 23 at 12:14 PM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 8:00 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 14 at 3:19 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : July 11, 2017
finance.yahoo.com - July 11 at 4:18 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Insider Anne-Marie Duliege Sells 5,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - July 2 at 7:32 AM
americanbankingnews.com logo Analysts Anticipate Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - July 1 at 12:12 AM
streetinsider.com logoRigel Pharma (RIGL) to Present Data on TAVALISSE (fostamatinib disodium) Phase 3 at EHA Conference on 6/24 - StreetInsider.com
www.streetinsider.com - June 23 at 9:37 AM
finance.yahoo.com logoRigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
finance.yahoo.com - June 23 at 9:37 AM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RIGL) : June 22, 2017
finance.yahoo.com - June 23 at 9:37 AM
zacks.com logoRigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
www.zacks.com - June 22 at 10:47 AM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : June 20, 2017
finance.yahoo.com - June 22 at 10:47 AM
fool.com logoHere's Why Rigel Pharmaceuticals Inc. Is Shining Extra Bright Today - Motley Fool
www.fool.com - June 21 at 4:17 AM
finance.yahoo.com logoRigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
finance.yahoo.com - June 21 at 4:17 AM
streetinsider.com logoPre-Open Movers 06/19: (CLVS) (RICE) (RIGL) Higher; (SGEN) (TSRO) (EQT) Lower (more...)
www.streetinsider.com - June 20 at 2:31 AM
finance.yahoo.com logoRigel Pharma Rises Following FDA Approval
finance.yahoo.com - June 20 at 2:31 AM
finance.yahoo.com logoHere's Why Rigel Pharmaceuticals Inc. Is Shining Extra Bright Today
finance.yahoo.com - June 20 at 2:31 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Receives Outperform Rating from BMO Capital Markets
www.americanbankingnews.com - June 19 at 7:36 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 19 at 2:48 PM
nasdaq.com logoRigel Pharma: FDA To Review NDA For TAVALISSE - Quick Facts
www.nasdaq.com - June 19 at 10:02 AM
finance.yahoo.com logoFDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP
finance.yahoo.com - June 19 at 10:02 AM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 8:37 PM
finance.yahoo.com logoImplied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
finance.yahoo.com - June 16 at 9:20 AM

Social

Chart

Rigel Pharmaceuticals (RIGL) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff